I???d like to start today by sharing some topline thoughts on our news that COMETRQ was approved for patients with progressive metastatic medullary thyroid cancer or MTC. First and foremost, I want to thank everyone who has helped us get here, especially the physicians and patients whose involvement in the clinical trial process made today possible.